GUTHRIE℠

Robert Packer Hospital
One Guthrie Square
Sayre, PA 18840-1698
Tel 570.888.6666

030-03013

May 21, 2002

Ms. Theresa Hall-Darden
United States Nuclear Regulatory Commission
Region 1
475 Allendale Rd.
King of Prussia, PA 19406-1415

Re: Amendment of Materials License 37-01893-01

Dear Ms. Hall-Darden:

This letter is to request an amendment to our above referenced materials license. We have recently added a permanent medical physicist to our medical staff and request the following changes:

- Addition of Joon Ho Park, MMSc as Medical Physicist and Radiation Safety Officer.
- Delete Thomas Padikal, PhD, on our license as Medical Physicist.
- Addition of Raymond Perez, DO as an authorized user of licensed materials.
- Delete Lanny Chuang, DO as Radiation Safety Officer.

I have attached a copy of materials license 45-09207-01 demonstrating Mr. Park's previous privileges as medical physicist on an NRC license. I have also included Mr. Park's resume. I believe Mr. Park meets the criteria for Radiation Safety Officer as defined by the NRC under Standard 35.900 part b, meeting both the educational requirements, as well as supervision under a Radiation Safety Officer identified as such on a Commission or Agreement State license that authorizes the medical use of byproduct material. Mr. Park is also eligible to complete the ABR therapeutic radiation physicist certification process this year.

I have also attached a copy of Radioactive Materials License 2989-1 from the State of Florida demonstrating privileges for Raymond Perez on a materials license in an agreement state.

Please note that Thomas Padikal, PhD has finished his temporary assignment at our institution and is no longer working here. Also, Dr. Chuang will continue to work at our organization and will remain an authorized user on our license, but will relinquish responsibility as Radiation Safety Officer to Mr. Park when our license is amended.

All proposed changes to our license have been reviewed by our Radiation Safety Committee. If you have any questions or comments, please do not hesitate to contact me directly at 570-882-5197.

Sincerely,

Jeff B. McBee

Jeff B. McBee
Administrative Director

cc: Lanny Chuang, DO

JOON HO PARK

OBJECTIVE

Employment as a medical physicist.

EDUCATION

1997 – 1999 University of Florida Gainesville, FL
Ph.D. candidate (discontinued)/Medical Physics

- Research assistant at the Shands Cancer Center.
- Completion of Ph.D. preliminary examination requirement.
- Co-authoring of two poster presentations for the 1999 AAPM annual meeting.
- Monte Carlo techniques for radiation transport (MCNP4b).
- Graduate level analytical radiation transport methods.
- Graduate level radiation interaction fundamentals.
- Preliminary works on automation of DMLC leafmotion generation.

1995 - 1997 Emory University Atlanta, GA
M.MSc./Radiation Oncology Physics

- A one-year of clinical experience.
- Dosimetry, Radiation oncology, Oncology, Radiation Biology, Diagnostic imaging, Nuclear Medicine, Health physics, Radiation shielding, Nuclear physics, Anatomy, and BioStatistics.

1992 - 1995 Georgia Institute of Technology Atlanta, GA
B.S./Physics

- Graduate level fundamental physics courses.
- Teaching assistant for the sophomore level physics curriculum.
- Induction to Sigma Pi Sigma.

PUBLICATIONS

Abstracts and poster presentation for the 1999 AAPM annual meeting

Use of dynamic multileaf collimator as dose compensator, Joon Ho Park, Cody Chen, Chihray Liu, Jatinder Palta.

Generation of EDW profile with dynamic multileaf collimator using segmented treatment table, Cody Chen, Joon Ho Park, Chihray Liu, Jatinder Palta.

5624 STARKEY RD • ROANOKE, VA 24014
HOME: (540) 769-6159 WORK: (540) 776-4162 E-MAIL joon_park@msn.com

PROFESSIONAL EXPERIENCE

2000 - Present CPRS, ltd. VA

Medical Physicist (Regional Coordinator)

- On-site consulting at the HCA Lewis-Gale Medical Center (Salem, VA)
- Commissioning and implementation of ADAC Pinnacle RTP systems.
- Varian 2100 C/D with 80 leaf MLC with EPID, VARIS R&V system, Varian Ximatron simulator, microSelctron HDR remote afterloader with Plato BPS.
- Prostate seed implants.
- Radiation Safety.
- Management of all aspects of equipment and dosimetry QA.
- Development of in-house software for the routine monitor unit calculations and other relevant clinical functions.
- Implementation and education of staff on the conformal radiation therapy and the basic concepts on radiation interactions pertaining to radiation therapy.
- Experiences with MultiData dosimetry system.

1999 - 2000 Baptist Health System of South Florida Miami, FL

Medical Physicist (contracted consultant)

- Commissioning and implementation of ADAC Pinnacle RTP systems (photon, electron and brachy modules) at both Baptist affiliated hospitals (Baptist hospital and South-Miami hospital).
- Commissioning and implementation of STP3 (Leibinger) based SRS at Baptist hospital.
- Implementation and education of staff on the conformal radiation therapy and the basic concepts on radiation interactions pertaining to radiation therapy (BAT ultrasound localization system).
- Experiences with MultiData dosimetry system.
- Clinical involvement in treatment planning in both external and brachy therapy programs.
- Commissioning and implementation of interfacing between ADAC Pinnacle RTP and Varian Varis R&V system.
- Commissioning of Varian 2100EX linear accelerator with Enhanced dynamic wedge and Millennium DMLC.

1999 RTSI Ft. Myers Ft. Lauderdale, FL

Medical Physicist

- Involvement in commissioning of Varian 2100EX and ADAC Pinnacle RTP.
- I-125 and Pd-103 prostate seed implants (both real-time and pre-plan), T&O, Sr-89 injection, Sr-90 Pterygium eye applicator.
- HDR procedures (micro selectron with plato treatment planning software).
- Treatment planning experience with ROCs, CMS focus and Prowess prostate treatment planning systems.
- Experiences with CRS dosimetry system.
- Clinical routine tasks including morning daily QA, chart checks, chart rounds and monthly and annual QA.

- Experience with IMPAC record and verify system.

1997 - 1999 University of Florida Gainesville, FL

Research assistant

- Monthly and yearly QA program involving Varian 600 and 2100 C/D (EDW and DMLC), Phillips SL25 and SL75, Theratron 1000 Co-60 unit (external beam units).
- Treatment planning experience with ROCs and ADAC pinnacle treatment planning systems (both external beams and brachytherapy).
- Experiences with Wellhofer dosimetry system (WP600 and WP700 and film scanning system) and Sun Nuclear diode array profiler.
- Limited experience with Varian Ximatron simulator and Picker AcQsim.
- Limited experience with IMPAC record and verify system.

1996 - 1997 Emory University Atlanta, GA

Radiation Oncology Physics resident

- Monthly and yearly QA program involving Varian 600 and 2300 C/D, (external beam units).
- QA experiences with nucletron HDR unit and Emory X-knife.
- Treatment planning experience in external beam radiation therapy using Emory implemented 3D treatment planning system and Render Plan 3D.
- Treatment planning experience with the SRS procedure.
- Treatment planning experience with brachytherapy procedures (excluding permanent implants).
- Limited experience with stereotactic interstitial implant therapy.
- Limited experience with Wellhofer dosimetry system (WP600)
- Limited experience with VARIS record and verify system.

PROFESSIONAL MEMBERSHIPS

Sigma Pi Sigma

American Association of Physicists in Medicine

ACCREDITATIONS

Completed written exam part of the ABR therapeutic radiation physics (10/2001). Eligible to complete the certification process in 2002.

Virginia department of health certified private investigator.

PROGRAMMING EXPERIENCE (PCS AND UNIX/LINUX BASED PLATFORMS)

- Visual Basic (implementation of site-specific Win32 based physics tools, including Monitor unit calculation and diode dosimetry tools with goal of developing an integrated system that will assist in the department daily routines and special procedures.)
- MatLab & IDL
- Fortran
- Visual C/C++

REFERENCES

William J. Walker	President/medical physicist	CPRS, ltd. (VA)
Jatinder Palta	Chief Physicist	Shands Cancer Center (UF)
Patton McGinley	Former Director of graduate program	Emory University

NRC FORM 374

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 1 OF 6 PAGES
Amendment No. 52

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	In accordance with the letter dated **September 25, 2001**
1. Lewis-Gale Medical Center$_{LLC}$	3. License No. 45-09207-01 is amended in its entirety to read as follows:
2. 1900 Electric Road Salem, Virginia 24153-7494	4. Expiration Date: November 30, 2005
	5. Docket No. 030-03333

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material identified in 10 CFR 35.100	A. Any radiopharmaceutical identified in 10 CFR 35.100	A. As needed
B. Any byproduct material identified in 10 CFR 35.200	B. Any radiopharmaceutical identified in 10 CFR 35.200	B. As needed
C. Iodine 131	C. Any unsealed form for preparation and administration as specified in §35.300	C. 555 gigabecquerels (GBq) [1.5 curies (Ci)]
D. Any byproduct material with a half-life less than 120 days, except iodine 131	D. Any form identified in 10 CFR 35.300 and initially distributed pursuant to 10 CFR Part 32 or an equivalent Agreement State regulation.	D. As needed
E. Any byproduct material identified in 10 CFR 35.400	E. Any brachytherapy sources identified in 10 CFR 35.400	E. As needed
F. Any byproduct material identified in 10 CFR 35.500	F. Any diagnostic source registered pursuant to 10 CFR 32.210 and identified in 10 CFR 35.500	F. See Item 9.F.
G. Strontium 90	G. Sealed source registered pursuant to 10 CFR 32.210	G. 33.33 megabecquerels (900 microcuries)
H. Iridium 192	H. Sealed Source (Byk Mallinckrodt, Model CI-L-BV)	H. 814 GBq (22 Ci) total (see Item 9.H)

NRC FORM 374A U.S. NUCLEAR REGULATORY COMMISSION	PAGE 2 of 6 PAGES
MATERIALS LICENSE SUPPLEMENTARY SHEET	License No. 45-09207-01
	Docket No. 030-03333
	Amendment No. 52

9. Authorized Use:

A. Medical use described in 10 CFR 35.100.

B. Medical use described in 10 CFR 35.200.

C. and D. Any radiopharmaceutical therapy approved in §35.300.

E. Medical use described in 10 CFR 35.400.

F. Sealed source contained in a compatible device (registered pursuant to 10 CFR 32.210 or an equivalent Agreement State regulation) for medical use identified in 10 CFR 35.500. The licensee may also possess one additional source in its shipping container for use incident to source exchange.

G. Instrument calibration.

H. One source not to exceed 370 GBq (10 Ci) in Nucletron-Oldeft Corporation Model Micro Selectron-HDR (080.000) remote afterloading brachytherapy irradiator for treatment of cancer patients, and one source not to exceed 444 GBq (12 Ci) for storage in its shipping container for decay to 370 GBq (10 Ci), incident to source replacement.

CONDITIONS

10. Licensed material shall be used only at the licensee's facilities located at Lewis-Gale Medical Center, 1900 Electric Road, Salem, Virginia, except that the HDR device identified in Subitems 6.H, 7.H, 8.H and 9.H shall be used only in the licensee's Clinic linear accelerator treatment room.

11. A. The Radiation Safety Officer (RSO) for this license is David M. Randolph, M.D., or in his absence, John M. Mathis, M.D.

B. The Brachytherapy Physicist for this license is Joon Ho Park.

NRC FORM 374A	U.S. NUCLEAR REGULATORY COMMISSION	PAGE 3 of 6 PAGES
MATERIALS LICENSE SUPPLEMENTARY SHEET		License No. 45-09207-01
		Docket No. 030-03333
		Amendment No. 52

12. Licensed material listed in Item 6 above is only authorized for use by, or under the supervision of, the following individuals for the materials and uses indicated:

	Authorized User	Material and Use
A.	Placido H. DeGuzman, M.D.	Medical use described in 10 CFR 35.100, 35.200, and 35.500.
B.	David M. Randolph, M.D.	Medical use described in 10 CFR 35.400, and for strontium 89 therapy identified in 10 CFR 35.300. Subitem H. for interstitial, intracavitary, intraluminal or topical treatment of cancer.
C.	Emily H. Lewis, M.D.	Medical use described in 10 CFR 35.100, 35.200, 35.300, and 35.500.
D.	Robert F. O'Brien, M.D.	Medical use described in 10 CFR 35.100, 35.200, 35.300 and 35.500.
E.	John M. Mathis, M.D.	Medical use described in 10 CFR 35.100, 35.200, 35.300, and 35.500.
F.	Robert G. Zeller, M.D.	Medical use described in 10 CFR 35.100 and 35.200.
G.	Richard A. Smith, M.D.	Medical use described in 10 CFR 35.100 and 35.200.
H.	Naiyer Imam, M.D.	Medical use described in 10 CFR 35.100 and 35.200.
I.	James D. Matthews, M.D.	Medical use described in 10 CFR 35.100, 35.200, 35.300, and 35.500.
J.	Neil F. O'Donohue, M.D.	Medical use described in 10 CFR 35.100 and 35.200.
K.	Debra Ann Chiarella, M.D.	Medical use described in 10 CFR 35.100 and 35.200.
L.	Brandon W. Chan, M.D.	Medical use described in 10 CFR 35.100 and 35.200.
M.	Patrick T. Rucker, M.D.	Medical use described in 10 CFR 35.100 and 35.200.

13. Sealed sources containing licensed material shall not be opened by the licensee.

14. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35 for establishing decommissioning financial assurance.

NRC FORM 374A	U.S. NUCLEAR REGULATORY COMMISSION	PAGE 4 of 6 PAGES
MATERIALS LICENSE SUPPLEMENTARY SHEET		License No. 45-09207-01
		Docket No. 030-03333
		Amendment No. 52

CONDITION NUMBERS 15 THROUGH 19 ARE APPLICABLE ONLY TO
HIGH DOSE RATE (HDR) REMOTE AFTERLOADING BRACHYTHERAPY UNIT(S)

15. In lieu of 10 CFR 35.404(a), immediately after retracting the source from the patient into its shielded position in the HDR remote afterloading brachytherapy unit, a radiation survey shall be made of the patient and the HDR remote afterloading brachytherapy unit with a portable radiation detection survey instrument to confirm that the source has been removed from the patient. Records of the survey shall be maintained in lieu of the record required in 10 CFR 35.404(b).

16. In lieu of the source inventory required in 10 CFR 35.406, the licensee shall:

    A. Promptly determine that all sources have returned to the safe, shielded position at the conclusion of each HDR remote afterloading brachytherapy procedure.

    B. Promptly make a survey of the area of use to confirm that no sources have been misplaced.

    C. Make a record of the survey including the survey instrument used, dose rate expressed in millirem per hour (mrem/hr) [microSieverts per hour (uSv/hr)], time, date and name of the individual making the survey.

    D. Retain the record of the survey in lieu of the record required in 10 CFR 35.406(d).

17. Prior to initiation of a treatment program, and subsequent to each source exchange, using the HDR remote afterloading brachytherapy unit(s), a radiation survey shall be made of:

    A. The irradiator source housing, with the source in the shielded position. The maximum radiation levels at 10 centimeters from the surface of the main source safe shall not exceed 1 mrem/hr (uSv/hr).

    B. All areas adjacent to the treatment room with the source in the "irradiation" position. The survey shall clearly establish that radiation levels in:

        1) restricted areas are not likely to cause personnel exposure in excess of the limits specified in 10 CFR 20.1201; and

        2) unrestricted areas do not exceed the limits specified in 10 CFR 20.1301.

NRC FORM 374A	U.S. NUCLEAR REGULATORY COMMISSION	PAGE 5 of 6 PAGES
MATERIALS LICENSE SUPPLEMENTARY SHEET		License No. 45-09207-01
		Docket No. 030-03333
		Amendment No. 52

18. The following shall be performed only by manufacturer's representatives or persons specifically authorized by the Commission or an Agreement State to perform such services:

    A. Installation and replacement of the sealed sources contained in the HDR remote afterloading brachytherapy unit(s).

    B. Any maintenance or repair operations on the HDR remote afterloading brachytherapy unit(s) listed in Item 9, Subitem(s) H involving work on the source safe, the source drive unit, or other mechanism that could expose the source, reduce the shielding around the source, or compromise the safety of the unit and result in increased radiation levels.

19. A. Access to the rooms housing the HDR remote afterloading brachytherapy unit shall be controlled by a door at each entrance.

    B. The entrance to the irradiation room shall be equipped with an electrical interlock system that will cause the source to return to the shielded position immediately upon opening of the entrance door. The interlock system shall be connected in such a manner that the source cannot be placed in the irradiation position until the entrance door is closed and the source "on-off" control is reset at the control panel.

    C. Electrical interlocks on the entrance door to the irradiator room shall be tested for proper operation at least once each day of use.

    D. In the event of malfunction of the door interlock, the irradiation device shall be locked in the "off" position and not used, except as may be necessary for repair or replacement of the interlock system, until the interlock system is shown to be functioning properly.

20. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below, except for minor changes in the medical use radiation safety procedures as provided in 10 CFR 35.31. The U. S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

    A. Applications dated:

        1) April 30, 1990
        2) May 16, 1995 [renewal]

NRC FORM 374A	U.S. NUCLEAR REGULATORY COMMISSION	PAGE 6 of 6 PAGES
MATERIALS LICENSE SUPPLEMENTARY SHEET		License No. 45-09207-01
		Docket No. 030-03333
		Amendment No. 52

20. B. Letters dated:

1) September 7, 1990 [add'l info re: bioassay program, hoods, dosimetry and action levels]
2) March 3, 1994 [procedures for use of strontium 89]
3) November 7, 1995 [fax re: qualification of new RSO w/ ltr dtd 10/31/95 providing add'l info re: security and exposure control for sealed sources]
4) January 23, 1996 [name change; add HDR use and procedures]
5) February 21, 1996 [add'l info re: HDR use and procedures]
6) August 12, 1996 [add topical treatment of cancer with HDR (See TAR dated June 26, 1996)]
7) October 29, 1997 [add/delete authorized users]
8) May 13, 1998 [add 2 users (R. O'Brien, J. Mathis); delete user (M. Bassignani)]
9) July 1, 1998 [name change (d/b/a Lewis-Gale Medical Center)]
10) January 14, 1999 [name change]
11) March 9, 1999 [delete 7 users (M. Zelenik, B. Banning, C. Ferguson, N. Adamson, J. Butler, R. Broadwell, J. Kiser); and add 4 users (R. Zeller, R. Smith, N. Imani, J. Matthews)]
12) March 19, 1999 [change RSO (D. Randolph)]
13) April 14, 1999 [fax re: change RSO (A. Markus)]
14) April 15, 1999 [fax re: add'l info of proposed RSO's training and experience)]
15) June 1, 1999 [change RSO (D. Randolph), Alt. RSO (J. Mathis), and Brachytherapy Physicist (R. Glossner); add one user (N. O'Donohue); and expand use of one user (R. O'Brien)]
16) August 13, 1999 [change RSO, additional qualifications for Matthews and O'Brien]
17) August 19, 1999 [clarification for new RSO experience]
18) September 20, 1999 [add 3 users (D. Chiarella, B. Chan, P. Rucker)]
19) July 11, 2000 [change Brachytherapy Physicist (S. Darwish)]
20) August 17, 2000 [fax re: change in Brachytherapy Physicist (J. Park)]
21) June 18, 2001 [new layout for Nuclear Med. Dept.]
22) September 25, 2001 [add Alt. RSO (J. Mathis); correct physicist's name]

FOR THE U. S. NUCLEAR REGULATORY COMMISSION

DATE DEC 07 2001

BY _____

Bryan A. Parker
Region II, Division of Nuclear Materials Safety
61 Forsyth Street, S.W., Suite 23T85
Atlanta, Georgia 30303-8931

N:\ACTIVE\45-09207-01 A52.wpd

STATE OF FLORIDA
DEPARTMENT OF HEALTH
BUREAU OF RADIATION CONTROL

RADIOACTIVE MATERIALS LICENSE

Pursuant to Chapter 404, Florida Statutes, and Chapter 64E-5, Florida Administrative Code (F.A.C.), and in reliance on statements and representations heretofore made by the licensee designated below, a license is hereby issued authorizing such licensee to receive, acquire, possess and transfer the radioactive material(s) designated below and to use such radioactive material(s) for the purpose(s) and at the place(s) designated below. This license is subject to all applicable rules, regulations and orders of the state of Florida, Department of Health now or hereafter in effect and to any conditions specified below.

Licensee	3. License Number: 2989-1
1. Name: NAVIX - MSO - PUNTA GORDA, INC.	is hereby amended in its entirety, with reference to correspondence dated 02/06/02.
2. Address: 2601 S. Bayshore Drive, # 500 Coconut Grove, FL 33133	4. Expiration Date: 02/28/2004 5. Category: 5C

6. Radioactive material (element and mass number)	7. Chemical And/Or Physical Form	8. Maximum Quantity Licensed Any Person(s) At Any One Time
A. Any radioactive material described in section 64E-5.626, F.A.C.	A. Any radiopharmaceutical for diagnostic use involving measurements of uptake, dilution or excretion as described in section 64E-5.626, F.A.C.	A. As necessary
B. Any radioactive material described in section 64E-5.627, F.A.C.	B. Any radiopharmaceutical for diagnostic use involving imaging and localization as described in section 64E-5.627, F.A.C., except gases and aerosols	B. As necessary
C. Any radioactive material described in section 64E-5.630, F.A.C.	C. Any radiopharmaceutical for therapeutic use as described in section 64E-5.630, F.A.C., except gold 198, and iodine 131 for the treatment of thyroid carcinoma	C. As necessary

STATE OF FLORIDA
DEPARTMENT OF HEALTH
BUREAU OF RADIATION CONTROL

9. Authorized Use

A. Any medical use described in section 64E-5.626, F.A.C.

B. Any medical use described in section 64E-5.627, F.A.C., except gases and aerosols.

C. Any medical use described in section 64E-5.630, F.A.C., except gold 198, and iodine 131 for the treatment of thyroid carcinoma.

Conditions

10. The authorized place of use is the licensee's facility located at 329 East Olympia Avenue, Punta Gorda, Florida 33950.

11. Failure to comply with the provisions of this license is a felony of the third degree pursuant to section 404.161, Florida Statutes. Also, violations may warrant an administrative fine of up to $1,000.00 per violation per day, pursuant to section 404.162, Florida Statutes.

12. A. The following individuals are authorized for the materials and uses as indicated:

64E-5.626, 64E-5.627, and 64E-5.630 (except gold 198 and iodine 131 for the treatment of thyroid carcinoma)	Melvyn J. Katzen, M.D.
64E-5.626, 64E-5.627, and 64E-5.630 (except gold 198, phosphorus 32, strontium 89, samarium 153, and iodine 131 for the treatment of thyroid carcinoma)	Margo H. Roca, M.D. Alberto Righi, M.D.
64E-5.626 and 64E-5.627	Raymond J. Perez, D.O.

B. The radiation safety officer is Alberto Righi, M.D.

C. Radiologic technologists who use and administer radioactive materials or perform brachytherapy or teletherapy procedures under the general supervision of an authorized user shall hold a valid certificate as required by Chapter 468, F.S.

13. Radioactive material transported on public thoroughfares shall be packaged, prepared for shipment, and transported in accordance with Title 49, Code of Federal Regulations and Chapter 64E-5, F.A.C.

STATE OF FLORIDA
DEPARTMENT OF HEALTH
BUREAU OF RADIATION CONTROL

14. Sealed sources containing licensed material shall not be opened.

15. The licensee shall not authorize release from confinement for medical care any patient administered a radiopharmaceutical until:

    A. The dose rate is less than 5 millirem (50 microsieverts) per hour at a distance of 1 meter; or

    B. The amount of radioactive material in the patient is less than 30 millicuries.

16. Any therapeutic dose of iodine 131 shall be received in capsule form only.

17. Phosphorus 32, strontium 89 or any other pure beta-emitting radiopharmaceuticals shall be received in single dose aliquots only.

18. The licensee shall implement the quality management program (QMP) as stated in Condition 19 and section 64E-5.611, F.A.C.

19. A. Except as specifically provided otherwise by this license, the licensee shall possess and use licensed material described in Items 6, 7, 8, and 9 of this license in accordance with statements, representations and procedures contained in the licensee's application dated October 13, 1998, signed by Miles E. Gilman, and correspondence dated:

    November 10, 1998, signed by Melvyn J. Katzen, M.D., F.A.C.R.;
    December 16, 1998,
    January 28, 1999, and
    June 13, 2001 (delegation of authority – Alberto Righi, M.D.), all signed by Miles E. Gilman, President.

    B. The licensee shall comply with all applicable requirements of Rule 64E-5, Florida Administrative Code, and these regulations shall supersede the licensee's statements in applications or correspondence, unless the statements are more restrictive than the regulations.

For the Bureau of Radiation Control:

Issuance Date: FEB 22 2007

Original Signed By
LIBBY MITCHELL

Libby Mitchell
Environmental Specialist II
Bin #C21
4052 Bald Cypress Way
Tallahassee, FL 32399-1741
(850) 245-4545

This is to acknowledge the receipt of your letter/application dated

5/28/2002, and to inform you that the initial processing which includes an administrative review has been performed.

AMEND. 37-01893-01

☑ There were no administrative omissions. Your application was assigned to a technical reviewer. Please note that the technical review may identify additional omissions or require additional information.

☐ Please provide to this office within 30 days of your receipt of this card

_____.

A copy of your action has been forwarded to our License Fee & Accounts Receivable Branch, who will contact you separately if there is a fee issue involved.

Your action has been assigned **Mail Control Number** 131561.
When calling to inquire about this action, please refer to this control number.
You may call us on (610) 337-5398, or 337-5260.

NRC FORM 532 (RI)
(6-96)

Sincerely,
Licensing Assistance Team Leader

	:	(FOR LFMS USE)
	:	INFORMATION FROM LTS
BETWEEN:	:	----------
	:	
License Fee Management Branch, ARM	:	Program Code: 02230
and	:	Status Code: 0
Regional Licensing Sections	:	Fee Category: 7C_3M
	:	Exp. Date: 20110930
	:	Fee Comments: CODE 23
	:	Decom Fin Assur Reqd: N
	::	

LICENSE FEE TRANSMITTAL

A. REGION I

1. APPLICATION ATTACHED
   Applicant/Licensee: GUTHRIE HEALTHCARE SYSTEM &
   Received Date: 20020528
   Docket No: 3003013
   Control No.: 131561
   License No.: 37-01893-01
   Action Type: Amendment

2. FEE ATTACHED
   Amount: ____/
   Check No.: ____/

3. COMMENTS

Signed M.A. Perkins
Date 6/4/2002

B. LICENSE FEE MANAGEMENT BRANCH (Check when milestone 03 is entered /__/)

1. Fee Category and Amount: _____

2. Correct Fee Paid. Application may be processed for:
   Amendment _____
   Renewal _____
   License _____

3. OTHER _____
   _____

Signed _____
Date _____